Application of Paclitaxel-loaded EGFR Peptide-conjugated Magnetic Polymeric Liposomes for Liver Cancer Therapy

Abstract

Developing the methodologies that allow for safe and effective delivery of therapeutic drugs to target sites is a very important research area in cancer therapy. In this study, polyethylene glycol (PEG)-coated magnetic polymeric liposome (MPL) nanoparticles (NPs) assembled from octadecyl quaternized carboxymethyl chitosan (OQC), PEGylated OQC, cholesterol, and magnetic NPs, and functionalized with epithelial growth factor receptor (EGFR) peptide, were successfully prepared for in-vivo liver targeting. The two-step liver targeting strategy, based on both magnetic force and EGFR peptide conjugation, was evaluated in a subcutaneous hepatocellular carcinoma model of nude mouse. The results showed that EGFR-conjugated MPLs not only accumulated in the liver by magnetic force, but could also diffuse into tumor cells as a result of EGFR targeting. In addition, paclitaxel (PTX) was incorporated into small EGFR-conjugated MPLs (102.0±0.7 nm), resulting in spherical particles with high drug encapsulation efficiency (>90%). The use of the magnetic targeting for enhancing the transport of PTX-loaded EGFR-conjugated MPLs to the tumor site was further confirmed by detecting PTX levels. In conclusion, PTX-loaded EGFR-conjugated MPLs could potentially be used as an effective drug delivery system for targeted liver cancer therapy.

Keywords

drug delivery / liver cancer / magnetic nanoparticles / quaternized chitosan / targeted therapy

References

[1] ZhongGC, LiuY, ChenN, et al.. Reproductive factors, menopausal hormone therapies and primary liver cancer risk: a systematicreview and dose-response meta-analysis of observational studies. Hum Reprod Update, 2016, 23(1): 126-138

[2] LingD, XiaH, ParkW, et al.. pH-sensitive nanoformulated triptolide as a targeted therapeutic strategy for hepatocellular carcinoma. ACS Nano, 2014, 8(8): 8027-8039

[3] WongMCS, HuangJLW, GeorgeJ, et al.. The changing epidemiology of liver diseases in the Asia-Pacific region. Nat Rev Gastroenterol Hepatol, 2019, 16(1): 57-73

[4] LlovetJM, Zucman-RossiJ, PikarskyE, et al.. Hepatocellular carcinoma. Nat Rev Dis Primers, 2016, 2: 16018

[5] PinyolR, MontalR, BassaganyasL, et al.. Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial. Gut, 2019, 68(6): 1065-1075

[6] AbdelmoneemMA, MahmoudM, ZakyA, et al.. Dual-Targeted Casein Micelles as Green Nanomedicine for Synergistic Phytotherapy of Hepatocellular Carcinoma. J Control Release, 2018, 287: 78-93

[7] PrietoJ, MeleroI, SangroB. Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol, 2015, 12(12): 681-700

[8] DhanasekaranR, VenkateshSK, TorbensonMS, et al.. Clinical implications of basic research in hepatocellular carcinoma. J Hepatol, 2016, 64(3): 736-745

[9] KwonS, SinghRK, KimTH, et al.. Luminescent mesoporous nanoreservoirs for the effective loading and intracellular delivery of therapeutic drugs. Acta Biomater, 2014, 10(3): 1431-1442

[10] PonnappanN, ChughA. Nanoparticle-Mediated Delivery of Therapeutic Drugs. Pharmaceut Med, 2015, 29(3): 155-167

[11] AndreuA, FairweatherN, MillerAD. Clostridium Neurotoxin Fragments as Potential Targeting Moieties for Liposomal Gene Delivery to the CNS. Chembiochem, 2008, 9(2): 219-231

[12] ValentP, AkinC, MetcalfeDD. FIP1L1/PDGFRA is a molecular marker of chronic eosinophilic leukaemia but not for systemic mastocytosis. Eur J Clin Invest, 2007, 37(2): 153-154

[13] LukasiewiczS, SzczepanowiczK, BlasiakE, et al.. Biocompatible Polymeric Nanoparticles as Promising Candidates for Drug Delivery. Langmuir, 2015, 31(23): 6415-6425

[14] ShiJ, KantoffPW, WoosterR, et al.. Cancer nanomedi cine: progress, challenges and opportunities. Nat Rev Cancer, 2017, 17(1): 20-37

[15] KhavariA, OrafaZ, HashemM, et al.. Different physical delivery systems: An important approach for delivery of biological molecules in vivo. J Paramed Sci, 2016, 7(1): 48

[16] AmemiyaY, TanakaT, YozaB, et al.. Novel detection system for biomolecules using nano-sized bacterial magnetic particles and magnetic force microscopy. J Biotechnol, 2005, 120(3): 308-314

[17] WangJ, MorabitoK, ErkersT, et al.. Capture and separation of biomolecules using magnetic beads in a simple microfluidic channel without an external flow device. Analyst, 2013, 138(21): 6573-6581

[18] ObaidG, ChambrierI, CookMJ, et al.. Cancer targeting with biomolecules: a comparative study of photodynamic therapy efficacy using antibody or lectin conjugated phthalocyanine-PEG gold nanoparticles. Photochem Photobiol Sci, 2015, 14(4): 737-747

[19] LuW, TanYZ, HuKL, et al.. Cationic albumin conjugated pegylated nanoparticle with its transcytosis ability and little toxicity against blood-brain barrier. Int J Pharm, 2005, 295(1–2): 247-260

[20] LockmanPR, OyewumiMO, KoziaraJM, et al.. Brain uptake of thiamine-coated nanoparticles. J Control Release, 2003, 93(3): 271-282

[21] TurnerF, SmithG, SachseC, et al.. Vegetable, fruit and meat consumption and potential risk modifying genes in relation to colorectal cancer. Int J Cancer, 2004, 112(2): 259-264

[22] ChavanpatilMD, KhdairA, GerardB, et al.. Surfactant-Polymer Nanoparticles Overcome P-Glycoprotein-Mediated Drug Efflux. Mol Pharm, 2007, 4(5): 730-738

[23] GibbsPE, MiralemT, Lerner-MarmaroshN, et al.. Nanoparticle Delivered Human Biliverdin Reductase-Based Peptide Increases Glucose Uptake by Activating IRK/Akt/GSK3 Axis: The Peptide Is Effective in the Cell and Wild-Type and Diabetic Ob/Ob Mice. J Diabetes Res, 2016, 2016(2): 4712053

[24] JafariM, KarunaratneDN, SweetingCM, et al.. Modification of a designed amphipathic cell-penetrating peptide and its effect on solubility, secondary structure, and uptake efficiency. Biochemistry, 2013, 52(20): 3428-3435

[25] FanM, YangD, LiangX, et al.. Design and biological activity of epidermal growth factor receptor-targeted peptide doxorubicin conjugate. Biomed Pharmacother, 2015, 70: 268-273

[26] ChengL, HuangFZ, ChengLF, et al.. GE11-modified liposomes for non-small cell lung cancer targeting: preparation, ex vitro and in vivo evaluation. Int J Nanomedicine, 2014, 9(Issue1): 921-935

[27] LiangX, ShiB, WangK, et al.. Development of self-assembling peptide nanovesicle with bilayers for enhanced EGFR-targeted drug and gene delivery. Biomaterials, 2016, 82: 194-207

[28] LiangXF, WangHJ, JiangXG, et al.. Development of monodispersed and functional magnetic polymeric liposomes via simple liposome method. J Nanopart Res, 2010, 12(5): 1723-1732

[29] ZhaoM, ChangJ, FuX, et al.. Nano-sized cationic polymeric magnetic liposomes significantly improves drug delivery to the brain in rats. J Drug Target, 2012, 20(5): 416-421

[30] GogoiM, JaiswalMK, SarmaHD, et al.. Biocompatibility and therapeutic evaluation of magnetic liposomes designed for self-controlled cancer hyperthermia and chemotherapy. Integr Biol (Camb), 2017, 9(6): 555-565

[31] RombergB, OussorenC, SnelCJ, et al.. Pharmacokinetics of poly(hydroxyethyl-l-asparagine)-coated liposomes is superior over that of PEG-coated liposomes at low lipid dose and upon repeated administration. Biochimica et Biophysica Acta, 2007, 1768(3): 0-743

[32] LiangX, SunY, DuanY, et al.. Synthesis and characterization of PEG-graft-quaternized chitosan and cationic polymeric liposomes for drug delivery. J Appl Polym Sci, 2012, 125(2): 1302-1309

[33] MaruyamaK. Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. Adv Drug Deliv Rev, 2011, 63(3): 161-169

[34] MohamedNK, HamadMA, HafezMZ, et al.. Nanomedicine in management of hepatocellular carcinoma: Challenges and opportunities. Int J Cancer, 2017, 140(7): 1475-1484

[35] SpangenbergHC, ThimmeR, BlumHE. Targeted therapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol, 2009, 6(7): 423-432

[36] AugustoV, JosepML. Targeted Therapies for Hepatocellular Carcinoma. Gastroenterology, 2011, 140(5): 1410-1426

[37] LiangXF, WangHJ, LuoH, et al.. Characterization of novel multifunctional cationic polymeric liposomes formed from octadecyl quaternized carboxymethyl chitosan/cholesterol and drug encapsulation. Langmuir, 2008, 24(14): 7147-7153

[38] SukJS, XuQ, KimN, et al.. PEGylation as a strategy for improving nanoparticle-based drug and gene deliver. Adv Drug Deliv Rev, 2016, 99(PtA): 28-51

[39] GabizonAA, PatilY, La-BeckNM. New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy. Drug Resist Updat, 2016, 29: 90-106

[40] QhattalHS, HyeT, AlaliA, et al.. Hyaluronan Polymer Length, Grafting Density, and Surface Poly(ethylene glycol) Coating Influence in Vivo Circulation and Tumor Targeting of Hyaluronan-Grafted Liposomes. ACS Nano, 2014, 8(6): 5423-5440

[41] LiangHF, ChenCT, ChenSC, et al.. Paclitaxel-loaded poly(g-glutamic acid)-poly(lactide) nanoparticles as a targeted drug delivery system for the treatment of liver cancer. Biomaterials, 2006, 27(9): 2051-2059

[42] RuttalaHB, RamasamyT, PoudalBK, et al.. Molecularly targeted co-delivery of a histone deacetylase inhibitor and paclitaxel by lipid-protein hybrid nanoparticles for synergistic combinational chemotherapy. Oncotarget, 2017, 8(9): 14925-14940

[43] ZhaoY, WangX, WangT, et al.. Acetylcholinesterase, a key prognostic predictor for hepatocellular carcinoma, suppresses cell growth and induces chemosensitization. Hepatology, 2011, 53(2): 493-503

[44] AbeylathSC, GantaS, IyerAK, et al.. Combinatorial-designed multifunctional polymeric nanosystems for tumor-targeted therapeuticdelivery. Acc Chem Res, 2011, 44(10): 1009-1017